文献
J-GLOBAL ID:202202290836378806
整理番号:22A0732788
抗PD1/PD-L1単独療法を受けた進行非小細胞肺癌患者における生存を予測するためのRECIST1.1の標的病変数の減少【JST・京大機械翻訳】
Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cancer undergoing anti-PD1/PD-L1 monotherapy
著者 (52件):
He Li-Na
(State Key Laboratory of Oncology in South China, Guangzhou, China)
,
He Li-Na
(Collaborative Innovation Center for Cancer Medicine, Guangzhou, China)
,
He Li-Na
(Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China)
,
Chen Tao
(State Key Laboratory of Oncology in South China, Guangzhou, China)
,
Chen Tao
(Collaborative Innovation Center for Cancer Medicine, Guangzhou, China)
,
Chen Tao
(Department of Nuclear Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China)
,
Fu Sha
(Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Pathology Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China)
,
Chen Chen
(State Key Laboratory of Oncology in South China, Guangzhou, China)
,
Chen Chen
(Collaborative Innovation Center for Cancer Medicine, Guangzhou, China)
,
Chen Chen
(Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China)
,
Jiang Yongluo
(State Key Laboratory of Oncology in South China, Guangzhou, China)
,
Jiang Yongluo
(Collaborative Innovation Center for Cancer Medicine, Guangzhou, China)
,
Jiang Yongluo
(Department of Nuclear Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China)
,
Zhang Xuanye
(State Key Laboratory of Oncology in South China, Guangzhou, China)
,
Zhang Xuanye
(Collaborative Innovation Center for Cancer Medicine, Guangzhou, China)
,
Zhang Xuanye
(Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China)
,
Du Wei
(State Key Laboratory of Oncology in South China, Guangzhou, China)
,
Du Wei
(Collaborative Innovation Center for Cancer Medicine, Guangzhou, China)
,
Du Wei
(Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China)
,
Li Haifeng
(State Key Laboratory of Oncology in South China, Guangzhou, China)
,
Li Haifeng
(Collaborative Innovation Center for Cancer Medicine, Guangzhou, China)
,
Li Haifeng
(Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China)
,
Wang Yixing
(State Key Laboratory of Oncology in South China, Guangzhou, China)
,
Wang Yixing
(Collaborative Innovation Center for Cancer Medicine, Guangzhou, China)
,
Wang Yixing
(Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China)
,
Ali Wael Abdullah Sultan
(State Key Laboratory of Oncology in South China, Guangzhou, China)
,
Ali Wael Abdullah Sultan
(Collaborative Innovation Center for Cancer Medicine, Guangzhou, China)
,
Ali Wael Abdullah Sultan
(Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China)
,
Zhou Yixin
(State Key Laboratory of Oncology in South China, Guangzhou, China)
,
Zhou Yixin
(Collaborative Innovation Center for Cancer Medicine, Guangzhou, China)
,
Zhou Yixin
(Department of VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, China)
,
Lin Zuan
(State Key Laboratory of Oncology in South China, Guangzhou, China)
,
Lin Zuan
(Collaborative Innovation Center for Cancer Medicine, Guangzhou, China)
,
Lin Zuan
(Department of Clinical Research, Sun Yat-sen University Cancer Center, Guangzhou, China)
,
Yang Yunpeng
(State Key Laboratory of Oncology in South China, Guangzhou, China)
,
Yang Yunpeng
(Collaborative Innovation Center for Cancer Medicine, Guangzhou, China)
,
Yang Yunpeng
(Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China)
,
Huang Yan
(State Key Laboratory of Oncology in South China, Guangzhou, China)
,
Huang Yan
(Collaborative Innovation Center for Cancer Medicine, Guangzhou, China)
,
Huang Yan
(Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China)
,
Zhao Hongyun
(State Key Laboratory of Oncology in South China, Guangzhou, China)
,
Zhao Hongyun
(Collaborative Innovation Center for Cancer Medicine, Guangzhou, China)
,
Zhao Hongyun
(Department of Clinical Research, Sun Yat-sen University Cancer Center, Guangzhou, China)
,
Fang Wenfeng
(State Key Laboratory of Oncology in South China, Guangzhou, China)
,
Fang Wenfeng
(Collaborative Innovation Center for Cancer Medicine, Guangzhou, China)
,
Fang Wenfeng
(Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China)
,
Zhang Li
(State Key Laboratory of Oncology in South China, Guangzhou, China)
,
Zhang Li
(Collaborative Innovation Center for Cancer Medicine, Guangzhou, China)
,
Zhang Li
(Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China)
,
Hong Shaodong
(State Key Laboratory of Oncology in South China, Guangzhou, China)
,
Hong Shaodong
(Collaborative Innovation Center for Cancer Medicine, Guangzhou, China)
,
Hong Shaodong
(Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China)
資料名:
Lung Cancer
(Lung Cancer)
巻:
165
ページ:
10-17
発行年:
2022年
JST資料番号:
W3184A
ISSN:
0169-5002
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)